Table 2 Randomized Trials for PCNSL
From: Current and emerging therapies for primary central nervous system lymphoma
| Â | Year | Diagnosis | N | Age (y) | Regimens (Arms) | Outcome | ||||
|---|---|---|---|---|---|---|---|---|---|---|
ORR/CR | PFS | OS | ||||||||
Induction | 2000 [51] | PCNSL | 53 | NA | WBRT(40) | WBRT(40)+CHOP | 18% vs 46% | NA | NA | |
2009 [52] | PCNSL, ND | 79 | 18-70 | MTX(3.5) | MTX(3.5)+AraC(2) | 40% vs 69% | NA | NA | ||
2015 [53] | PCNSL, ND | 95 | ≥60 | MTX(3.5)+TMZ(150) | MTX(3.5)+Pro(100)+V(1.4)+AraC(3) | 71% vs 82% | 6.1m vs 9.5m | NA | ||
2016 [54] | PCNSL, ND | 219 | 18-70 | MTX(3.5)+AraC(2) | MTX(3.5)+AraC(2)+R(375) | MTX(3.5)+AraC(2)+R(375)+T(30) (MATRix) | 53% vs 74% vs 87% | 42% vs 56% vs 69% | NA | |
2018 [55] | PCNSL, ND | 49 | 14-69 | MTX(3.5)+ AraC(1.0) | F(100)+Ten(60)+DXM(40) | 40% vs 33% | NA | NA | ||
2019 [56] | PCNSL, ND | 199 | 18-70 | MTX(3.0)+BCNU(100)+Ten(100)+Pred(60) | R(375, weekly)+MTX(3.0)+BCNU(100)+Ten(100)+Pred(60) | 86% vs 86% | (≤60 y) 26.3m vs 59.9m (>60 y) 19.6m vs 14.6m | (≤60 y) 56.7m vs not reached (>60 y) 49.2m vs 34.9m | ||
Consolidation | 2010 [57] | PCNSL, ND | 318 | 55-69 | w/w | WBRT(45) | NA | 11.9m vs 18.3m | 37.1m vs 32.4m | |
2017 [58] | PCNSL, ND | 118 | 18-70 | WBRT | ASCT | 95% vs 93% | NA | NA | ||
2017 [59] | PCNSL, ND | 318 | 55-69 | w/w | WBRT(45) | Reduced QoL and lower value of MMSE in WBRT arm | ||||
2019 [60] | PCNSL, ND | 140 | 18-60 | WBRT | ASCT | NA | 63% vs 87% | Cognitive impairment after WBRT | ||